KalVista Pharmaceuticals, Inc. KALV R2K

Healthcare · Biotechnology · United States

https://www.kalvista.com

KalVista Pharmaceuticals, Inc., a biopharmaceutical company, develops oral therapies for individuals for rare diseases with unmet needs. Its lead product candidate is EKTERLY, a fast-acting potent inhibitor of plasma kallikrein for the treatment of acute attacks of hereditary angioedema (HAE). The company is also developing is developing an orally disintegrating tablet formulation; KONFIDENT-KID for pediatric use with HAE; KONFIDENT; and KONFIDENT-S to evaluate sebetralstat and ODT formulation in adolescent and adult patients. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.

Market & Price

Market Cap

$1.43B

Current Price

$26.87

High / Low (52W)

$26.87 / $10.76

Beta

-0.12

Valuation

Stock P/E

Industry PE

23.65

Forward P/E

22.45

PEG Ratio

Book Value

$-0.05

Price to Book

-506.98

P/S

12.50

EV/EBITDA

-10.33

Dividend Yield

Profitability & Returns

ROCE

-62.68%

ROE

ROA

Profit Margin

Op Margin

-57.37%

EPS (Latest Qtr)

$-0.43

EPS (TTM)

$-3.94

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

4.97

Current Ratio

5.17

Debt

$284.31M

Total Assets

$335.38M

Current Assets

$320.15M

Working Capital

$262.79M

Ownership

Promoter Holding

1.72%

Chg in Prom Hold

FII / Inst Holding

131.35%

Chg in FII Hold

Financial Snapshot

Enterprise Value

$1.43B

Total Revenue (TTM)

$114.48M

EBITDA

$-138.45M

Free Cash Flow

Operating Cash Flow

$-89.32M

Shares Outstanding

53.24M

Gross Margin

51.07%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

-40.93%

Revenue (YoY)

Earnings (YoY)

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Earnings shrank at -40.9% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	KALV KalVista Pharmaceuticals, Inc. R2K	26.87	-	$1.43B	-	-62.68%	-	-	-40.93%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Sep 2016	Oct 2016	Jan 2017	Apr 2017	Jul 2017	Oct 2017	Jan 2018	Apr 2018	Jul 2018	Oct 2018	Jan 2019	Apr 2019	Jul 2019	Oct 2019	Jan 2020	Apr 2020	Jul 2020	Oct 2020	Jan 2021	Jul 2021	Oct 2021	Jan 2022	Jul 2022	Oct 2022	Jan 2023	Jul 2023	Oct 2023	Jan 2024	Mar 2024	Jun 2024	Jul 2024	Sep 2024	Oct 2024	Jan 2025	Mar 2025	Apr 2025	Jun 2025	Jul 2025	Sep 2025	Mar 2026
Revenue	-	-	-	-	96.00K	1.13M	2.33M	4.84M	3.72M	5.59M	3.89M	2.93M	3.37M	3.92M	1.58M	3.82M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	1.43M	13.69M	40.86M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	590.00K	1.23M	3.09M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	836.00K	12.46M	37.77M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42.94M	-	50.02M	-	59.84M	58.51M	61.22M
Operating Income	-2.40M	-4.03M	-8.12M	-	-5.45M	-5.94M	-4.35M	-	-7.01M	-4.89M	-6.66M	-	-9.56M	-9.29M	-12.72M	-	-14.44M	-12.78M	-12.66M	-19.52M	-23.60M	-26.68M	-26.32M	-25.88M	-26.95M	-29.09M	-29.75M	-33.15M	-	-	-44.22M	-43.48M	-	-42.94M	-49.71M	-50.02M	-	-59.01M	-46.05M	-23.44M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-41.19M	-	-49.88M	-	-54.16M	-42.57M	-17.55M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.84M	-	2.94M	-	3.52M	4.76M	5.59M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-44.26M	-	-53.08M	-	-57.94M	-47.33M	-23.49M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.25M	-	-855.00K	-	2.16M	2.16M	0
Net Income	-2.38M	-3.30M	-7.64M	-4.20M	-4.93M	-4.99M	-5.23M	-657.00K	-5.03M	-3.30M	-3.96M	-8.53M	-7.34M	-5.90M	-9.29M	-6.58M	-10.81M	-10.43M	-10.05M	-16.11M	-19.65M	-22.47M	-23.04M	-22.26M	-21.30M	-25.32M	-27.65M	-29.03M	-43.10M	-40.34M	-40.44M	-39.08M	-	-48.51M	-51.84M	-52.23M	-57.60M	-60.10M	-49.48M	-23.49M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.66	-0.80	-0.92	-0.94	-0.90	-0.75	-0.74	-0.80	-0.84	-	-	-0.87	-0.84	-0.91	-0.92	-0.98	-	-	-1.12	-0.92	-0.43
R&D Expense	332.00K	2.93M	3.34M	-	3.48M	4.36M	4.55M	-	8.36M	7.88M	7.65M	-	9.69M	9.79M	11.23M	-	11.16M	9.15M	9.10M	13.67M	17.55M	19.74M	18.19M	18.08M	20.06M	19.31M	19.09M	22.52M	-	-	26.61M	18.68M	16.61M	12.59M	14.17M	-	-	15.16M	11.99M	12.42M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Revenue	-	-	-	-	-	1.50M	8.39M	16.13M	12.69M	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	81.31M	95.09M	131.99M	182.98M
Operating Income	-5.22M	-11.68M	-8.09M	-21.04M	-15.18M	-22.34M	-18.70M	-29.82M	-40.53M	-57.92M	-81.31M	-95.09M	-131.99M	-182.98M
EBITDA	-	-	-	-	-	-	-	-	-	-	-80.75M	-94.37M	-125.83M	-173.33M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	0	5.79M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-82.34M	-92.91M	-126.64M	-180.05M
Tax Provision	-	-	-	-	-	-	-	-	-	-	0	0	0	3.39M
Net Income	-5.68M	-13.36M	-7.23M	-24.85M	-11.44M	-18.60M	-15.80M	-20.82M	-29.12M	-46.24M	-82.34M	-92.91M	-126.64M	-183.44M
Diluted EPS	-	-	-	-	-	-	-	-	-1.64	-2.42	-3.36	-3.33	-3.44	-3.69
R&D Expense	4.23M	8.29M	8.29M	16.20M	14.66M	12.67M	18.24M	35.02M	40.19M	41.29M	70.17M	80.28M	86.17M	71.71M

Compounded Sales Growth

5 Years:	-
1 Year:	-

Compounded Profit Growth

5 Years:	-40.93%
1 Year:	-

Stock Price Performance

1 Year:	+127.71%
6 Months:	+102.33%
3 Months:	+65.05%
1 Month:	+0.75%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Apr 2014	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025	Dec 2025
Total Assets	-	-	-	6.64M	-	56.79M	24.75M	34.34M	61.39M	118.13M	92.53M	272.01M	203.88M	183.20M	235.40M	250.77M	335.38M
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	172.33M	225.69M	241.69M	320.15M
Cash & Equivalents	8.24M	9.78M	481.00K	3.90M	2.53M	53.72M	21.76M	30.95M	51.05M	32.01M	15.79M	50.59M	30.73M	56.24M	31.79M	131.62M	229.34M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	3.43M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2.59M
Total Liabilities	-	-	-	11.27M	-	7.48M	-	-	-	-	-	-	-	22.18M	28.82M	155.38M	338.09M
Current Liabilities	-	-	-	7.09M	-	4.27M	3.25M	3.02M	23.22M	18.05M	7.72M	9.77M	11.58M	15.03M	22.81M	45.17M	57.35M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	139.23M
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	8.23M	7.32M	6.31M	151.57M
Total Equity	-28.29M	-33.71M	-16.21M	-44.18M	-23.55M	49.31M	-37.11M	31.33M	27.25M	96.74M	83.75M	257.19M	185.09M	161.03M	206.58M	95.39M	-2.71M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	34.17M	42.52M	49.76M	50.90M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Operating Cash Flow	-	-	-	-	-13.16M	-23.72M	10.56M	-36.37M	-44.82M	-30.17M	-78.13M	-75.26M	-89.23M	-152.91M
Investing Cash Flow	-	-	-	-	-11.00K	34.06M	-1.43M	-69.42M	16.75M	-147.65M	57.86M	41.41M	-84.72M	91.02M
Financing Cash Flow	-	-	-	-	33.00M	2.00K	8.99M	87.94M	11.58M	212.12M	1.58M	58.12M	150.71M	159.73M
Capital Expenditure	-18.00K	-159.00K	-125.00K	-659.00K	-11.00K	-74.00K	-1.43M	-1.08M	-220.00K	-82.00K	-931.00K	-1.20M	-443.00K	-929.00K
Free Cash Flow	-	-	-	-	-13.17M	-23.80M	9.13M	-37.45M	-45.04M	-30.25M	-79.06M	-76.46M	-89.67M	-153.84M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-18.69M	24.27M	-23.24M	97.84M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Apr 2015	Dec 2015	Apr 2016	Apr 2017	Apr 2018	Apr 2019	Apr 2020	Apr 2021	Apr 2022	Apr 2023	Apr 2024	Apr 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Margin %	-	-	-	-	-	-1,485.3%	-222.8%	-184.9%	-319.4%	-	-	-	-	-
Net Margin %	-	-	-	-	-	-1,236.9%	-188.3%	-129.1%	-229.4%	-	-	-	-	-
ROE %	16.8%	30.2%	30.7%	-50.4%	30.8%	-59.4%	-58.0%	-21.5%	-34.8%	-18.0%	-44.5%	-57.7%	-61.3%	-192.3%
ROCE %	-	2,600.7%	-	-40.1%	-70.6%	-71.3%	-49.0%	-29.8%	-47.8%	-22.1%	-42.3%	-56.5%	-62.1%	-89.0%

Shareholding Pattern

Insiders

1.72%

Institutions

131.35%

Public Float

133.66%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Venrock Adviser, LLC	12.16%	6.47M	$173.97M
2	Frazier Life Sciences Management, L.P.	9.32%	4.96M	$133.30M
3	Suvretta Capital Management, LLC	8.96%	4.77M	$128.14M
4	Tang Capital Management, LLC	8.59%	4.57M	$122.89M
5	Blackrock Inc.	7.13%	3.80M	$102.00M
6	SilverArc Capital Management, LLC	5.40%	2.88M	$77.29M
7	Capital World Investors	5.28%	2.81M	$75.47M
8	Point72 Asset Management, L.P.	4.01%	2.14M	$57.42M
9	State Street Corporation	3.67%	1.96M	$52.55M
10	Millennium Management Llc	3.59%	1.91M	$51.38M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for KALV

No recent headlines available.

KALV · Healthcare